BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing